FindTrial
Sign In

Expression and significance of GLI3 and cell proliferation index Ki67 in intrahepatic cholangiocarcinoma

Expression and significance of GLI3 and cell proliferation index Ki67 in intrahepatic cholangiocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033753
Enrollment
Unknown
Registered
2020-06-11
Start date
2020-06-18
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrahepatic cholangiocarcinoma(ICC)

Interventions

case series:Nil

Sponsors

The First people's Hospital of Jingmen
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The diagnostic standard of intrahepatic cholangiocarcinoma should refer to the standard formulated by the Chinese Medical Association; 2. According to the TNM analysis of the 8th edition of UICC, the clinicopathological staging was carried out; 3. Patients confirmed by pathological examination; 4. The patients had no history of radiotherapy and chemotherapy before operation; 5. All data of patients are complete.

Exclusion criteria

Exclusion criteria: 1. Patients with metastatic intrahepatic cholangiocarcinoma; 2. Patients not confirmed by pathological examination; 3. Patients with incomplete and irregular sample information.

Design outcomes

Primary

MeasureTime frame
GLI3;—

Countries

China

Contacts

Public ContactDuan Rui

The First People's Hospital of Jingmen

duanrui@sina.com+86 13607269899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026